


RealRate

CONSULTING & SERVICES 2022



Pharma Bio Serv Inc Rank 4 of 30







CONSULTING & SERVICES 2022





Pharma Bio Serv Inc Rank 4 of 30

The relative strengths and weaknesses of Pharma Bio Serv Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharma Bio Serv Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 164% points. The greatest weakness of Pharma Bio Serv Inc is the variable Revenue from Contract with Customer, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 157% points above the market average of 30%.

Input Variable	Value in 1000 USD
Assets, Current	22,822
Assets, Noncurrent	459
Cost of Revenues	14,755
General And Administrative Expense	9,214
Intangible Assets	0
Labor Expense	0
Liabilities, Current	2,651
Liabilities, Non-Current	487
Operating Lease Assets	640
Other Assets	0
Other Compr. Net Income	-16
Other Expenses	213
Other Liabilities	1,868
Other Net Income	1,978

Output Variable	Value in 1000 USD
Assets	23,921
Liabilities	5,007
Expenses	24,182
Revenues	20,115
Stockholders Equity	18,914
Net Income	-2,089
Comprehensive Net Income	-2,105
Economic Capital Ratio	187%





RealRate

CONSULTING & SERVICES 2022



Pharma Bio Serv Inc Rank 4 of 30

Input Variable	Value in 1000 USD
Other Revenues	20,115
Revenue from Contract with Customer	0
Revenue from Reimbursement	0

